Intra-Cellular Therapies Inc represents a commitment to innovative solutions in the field of neuroscience. They believe in advancing drug discovery and development to improve the lives of patients with neurological and psychiatric disorders. With a focus on intracellular signaling pathways, the company aims to revolutionize treatment options for conditions such as schizophrenia and bipolar disorder. Intra-Cellular Therapies Inc's corporate philosophy encompasses scientific excellence, integrity, and a patient-centric approach. By continuously pushing boundaries and addressing unmet medical needs, they strive to make a meaningful impact on mental health outcomes.

Intra-Cellular Therapies Inc is primarily present in the United States.

Intra-Cellular Therapies Inc has achieved several significant milestones. One of the notable accomplishments is the approval of their drug, lumateperone, by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults. This milestone marked a major breakthrough in the field of mental health. In addition, the company has also successfully completed various clinical trials, demonstrating the efficacy and safety of their innovative treatment options. Furthermore, Intra-Cellular Therapies Inc has established strategic partnerships and collaborations with renowned pharmaceutical companies, which further validates their position as a leader in the industry. These milestones highlight the company's dedication to addressing unmet medical needs and advancing the field of neuroscience.

Intra-Cellular Therapies Inc is a pharmaceutical company specializing in the discovery and development of therapies for central nervous system disorders. Established in 2002, the company aims to revolutionize the treatment of psychiatric and neurological conditions through innovative science and novel drug targets. With a focus on intracellular signal transduction pathways, Intra-Cellular Therapies Inc has made significant strides in developing its lead product candidate, lumateperone, for schizophrenia and bipolar disorder. The company's history showcases its dedication to advancing scientific knowledge and improving patients' lives by addressing unmet medical needs in mental health.

The main competitors of Intra-Cellular Therapies Inc in the market include pharmaceutical companies such as Allergan plc, Johnson & Johnson, and Novartis AG. These companies also operate in the field of developing innovative therapies for mental health disorders and neurological conditions. However, Intra-Cellular Therapies Inc distinguishes itself through its unique approach to developing small molecule drugs that target intracellular signaling pathways. By leveraging its expertise in neuroscience, the company aims to differentiate its products and provide novel treatment options for mental illnesses and other related diseases.

Intra-Cellular Therapies Inc is primarily active in the biopharmaceutical industry.

The business model of Intra-Cellular Therapies Inc focuses on developing innovative treatments for neuropsychiatric and neurological disorders. The company aims to address unmet medical needs by researching and developing novel drugs with a focus on the intracellular signaling pathways involved in these disorders. Intra-Cellular Therapies Inc is dedicated to delivering safe and effective therapeutics through a deep understanding of the biology and physiology of the central nervous system. The company's commitment to scientific excellence and clinical development drives its efforts to improve the lives of patients suffering from these debilitating conditions.

Intra-Cellular Therapies KGV ir -114,17.

Intra-Cellular Therapies KUV ir 9,80.

AlleAktien kvalitātes vērtējums Intra-Cellular Therapies ir 6/10.

gaidāmā Intra-Cellular Therapies apgrozījums ir 675,98 milj. USD.

gaidāmā Intra-Cellular Therapies peļņa ir -58,00 milj. USD.

Intra-Cellular Therapies Inc ("ITCI") is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and other serious diseases. ITCI's business model is based on identifying and developing new drugs for the treatment of diseases that currently have no satisfactory treatment options. ITCI currently operates in two main areas: psychiatry and neurology. In the psychiatry field, the company is focused on developing drugs for the treatment of schizophrenia, bipolar disorders, and major depressions. In the neurology field, ITCI is developing novel drugs for the treatment of Parkinson's disease, Huntington's disease, and other neurological disorders. The flagship product of ITCI is Lumateperone, a novel once-daily medication for the treatment of schizophrenia. Lumateperone has been developed by ITCI to treat the symptoms of schizophrenia while improving the patient's cognitive function. Lumateperone is also intended to be an alternative to the currently available antipsychotic therapies, with significantly reduced side effects. ITCI has submitted an application for approval of Lumateperone in the United States and expects a decision from the US Food and Drug Administration (FDA) soon. ITCI is also in the early stages of developing drugs for the treatment of neurological diseases such as Parkinson's disease and Huntington's disease. In this area, the company collaborates closely with experts from the academic world to identify new drug candidates and test them in clinical trials. To finance its business activities, ITCI raises investments from institutional investors and strategic partners. The company has successfully completed several financing rounds in the past, enabling it to advance its research and development activities. In the long term, ITCI plans to expand its business by entering new markets and collaborating with other companies and research institutions. The company aims to strengthen its position in the field of novel therapies for neurological disorders and expand its range of innovative drugs for use in the CNS field. Overall, ITCI adopts a strategy of diversification and growth. By exploring new therapy areas and collaborating with other companies and research institutions, the company seeks to increase its competitiveness and establish itself as a leading provider of innovative drugs for neurological disorders.

Intra-Cellular Therapies izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Intra-Cellular Therapies vai uzņēmums nedod dividendes.

Intra-Cellular Therapies ISIN ir US46116X1019.

Intra-Cellular Therapies WKN ir A1XDTL.

Intra-Cellular Therapies simbols ir ITCI.

Pēdējo 12 mēnešu laikā Intra-Cellular Therapies maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Intra-Cellular Therapies plāno maksāt dividendes 0 USD apmērā.

Intra-Cellular Therapies pašreizējā dividendu rentabilitāte ir .

Intra-Cellular Therapies maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Intra-Cellular Therapies pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Intra-Cellular Therapies tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Intra-Cellular Therapies apmērā 0 USD, kas tika izmaksāta 5.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 5.07.2024..

Pēdējās dividendes izmaksa notika 5.07.2024..

Gadā 2023, Intra-Cellular Therapies izmaksāja 0 USD dividendes.

Intra-Cellular Therapies dividendes tiek izmaksātas USD.